Stevenson et al. reported that silencing the GPCR G-protein–coupled receptor galanin receptor 1 (GalR1) enhanced the effects of chemotherapy in drug-sensitive and resistant colorectal cancer cell lines [30]. This evidence concerns the gene GALR1 and colorectal cancer.